IBRX ImmunityBio, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Development and commercialization of biologic drugs, with focus on regulatory approvals and post-marketing requirements
• • New emphasis on commercialization efforts for approved product ANKTIVA and building sales, marketing, and distribution capabilities
• • Strategic shift toward handling complex FDA accelerated approval pathways and orphan drug exclusivity following 2026 Orphan Drug Act codification
• • Post-marketing commitments for ANKTIVA include QUILT-3.032 trial completion by end of 2029 and annual FDA reporting up to 4 years
• • Increased focus on cybersecurity risks and use of AI in business, highlighting vulnerabilities and operational disruption potentials

Risk Factors

• • Regulatory risk from potential NCCN guideline decision on BCG-unresponsive NMIBC papillary-only disease expansion expected Q1/Q2 2026
• • Geopolitical exposure via dependency on 33 countries with ANKTIVA approval including US, UK, EU, Saudi Arabia, and MENA launches
• • Supply vulnerability as company supports FDA Expanded Access Program for rBCG to address U.S. supply constraints
• • Competitive risk from CPI combination therapies in metastatic NSCLC with conditional SFDA approval and planned commercial launch in 60 days
• • Financial risk in rapid revenue growth: ANKTIVA sales $113M FY2025, 700% YoY increase, requiring scaling of 85-person EU sales force and global partnerships

Management Discussion & Analysis

• • Revenue started from ANKTIVA sales since May 2024; no dollar amounts or YoY change disclosed
• • Operating expenses expected to increase substantially due to commercialization and R&D expansion; no margin % figures provided
• • No segment-specific performance data or best/worst performing segment disclosed
• • Cash and equivalents plus sales and potential equity offerings expected to fund operations for next 12 months; no buyback/dividend/capex details provided
• • Management highlights significant funding risks, need for additional capital to sustain operations, and regulatory/commercialization uncertainties impacting future outlook

What are the latest IBRX SEC filings in 2026?

ImmunityBio, Inc. (IBRX) has filed a 10-K annual report on February 23, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did IBRX file its most recent 10-K annual report?

ImmunityBio, Inc. (IBRX) filed its most recent 10-K annual report on February 23, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view IBRX 10-Q quarterly reports?

ImmunityBio, Inc. (IBRX)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every IBRX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has IBRX filed recently?

ImmunityBio, Inc. (IBRX)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find IBRX insider trading activity (Form 4)?

SignalX aggregates every IBRX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does IBRX file with the SEC?

ImmunityBio, Inc. (IBRX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new IBRX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ImmunityBio, Inc. (IBRX).

What is IBRX's SEC CIK number?

ImmunityBio, Inc. (IBRX)'s SEC CIK (Central Index Key) number is 1326110. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1326110 to look up all IBRX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find IBRX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from ImmunityBio, Inc. (IBRX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.